News & Trends
-
08 2021-12 Video Interpretation of Phase II Clinical Trial Results of Project NHT210118
See Annex 1: Phase II Promotion Video - 2.5 minutes
Learn more -
15 2021-08 NHT210118 Phase II Clinical Trial Paper is Published in Hepatology, the Best Journal on Liver Disease
A Paper on Phase II Clinical Trial Results of Innovative Therapeutic Hepatitis B Vaccine (Mimogen-based) (ɛPA-44 or Ipa in Chinese) developed by the team led by Prof. Wu Yuzhang from the Army Medical University was published on August 15 in Hepatology (https:doi.org/10.1002/hep.32109), the best journal on liver disease. This study was completed by 15 top clinical sites in China, including the Peking University People''s Hospital. The corresponding author of the Paper was Prof. Wu Yuzhang from the
Learn more -
06 2021-05 NHT210118 Project Kick-off Meeting is held at Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
NHT210118 Project Kick-off Meeting is held at Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Learn more -
04 2021-02 Novel Peptide Bioscience Co., Ltd. Officially Starts its Phase III Clinical Trial of Project NHT210118
On February 4, 2021 (BJT), the Project "NHT210118" with the drug name "Therapeutic (Synthetic Peptide) Hepatitis B Vaccine" was officially started.
Learn more